Secondly, in a prophylactic setting, the iPSC vaccine can be generated to treat individuals at high risk for developing cancers, such as patients with Lynch syndrome, Li-Fraumeni syndrome, hereditary chronic pancreatitis (Lowenfels et al., 1997; Weiss, 2014), chronic hepatitis B infection (Sherman et al., 1995), or pathogenic germline mutations in BRCA1/2 genes. The gene discussed is BRCA1; the disease is Li-Fraumeni syndrome.